A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Small Cell Lung Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has histologically or cytologically confirmed diagnosis of Extensive-Stage Small Cell Lung Cancer in need of first-line therapy. 2. Has extensive-stage Small Cell Lung Cancer defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition.

You may not be eligible for this study if the following are true:

  • 1. Has had major surgery within 3 weeks before first dose of study interventions. 2. Has a preexisting =Grade 3 gastrointestinal or non-gastrointestinal fistula. 3. Has urine protein =1 g/24 hours.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.